Kadimastem (Israel) Today
KDST Stock | ILA 1,189 14.00 1.19% |
Performance13 of 100
| Odds Of DistressLess than 34
|
Kadimastem is trading at 1189.00 as of the 22nd of December 2024, a 1.19 percent increase since the beginning of the trading day. The stock's open price was 1175.0. Kadimastem has about a 34 percent probability of financial distress in the next few years of operation but had a somewhat good performance during the last 90 days. The performance scores are derived for the period starting the 22nd of November 2024 and ending today, the 22nd of December 2024. Click here to learn more.
Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. The company was founded in 2008 and is based in Ness Ziona, Israel. KADIMASTEM operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. The company has 35.76 M outstanding shares. More on Kadimastem
Moving together with Kadimastem Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Kadimastem Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Kadimastem's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Kadimastem or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CEO | Ram Epstein |
Thematic Idea | Healthcare (View all Themes) |
Business Concentration | Healthcare, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Kadimastem (KDST) is traded on Tel Aviv Stock Exchange in Israel and employs 23 people. The company currently falls under 'Micro-Cap' category with a current market capitalization of 30.32 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Kadimastem's market, we take the total number of its shares issued and multiply it by Kadimastem's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Kadimastem operates under Biotechnology sector and is part of Health Care industry. The entity has 35.76 M outstanding shares.
Kadimastem has accumulated about 5.43 M in cash with (21.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.28.
Check Kadimastem Probability Of Bankruptcy
Ownership AllocationKadimastem maintains a total of 35.76 Million outstanding shares. Kadimastem holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Kadimastem Ownership Details
Kadimastem Risk Profiles
Although Kadimastem's alpha and beta are two of the key measurements used to evaluate Kadimastem's performance over the market, the standard measures of volatility play an important role as well.
Mean Deviation | 4.93 | |||
Semi Deviation | 4.57 | |||
Standard Deviation | 8.0 | |||
Variance | 63.98 |
Kadimastem Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Kadimastem without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Performance Analysis Now
Performance AnalysisCheck effects of mean-variance optimization against your current asset allocation |
All Next | Launch Module |
Kadimastem Corporate Directors
Keren Tzlill | External Director | Profile | |
David Sultan | Independent Director | Profile | |
Michel Revel | Chief Scientific Officer-Services Provider, Director | Profile | |
Joseph Eldor | Director | Profile |
Other Information on Investing in Kadimastem Stock
Kadimastem financial ratios help investors to determine whether Kadimastem Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Kadimastem with respect to the benefits of owning Kadimastem security.